$48.18 Million in Sales Expected for Enanta Pharmaceuticals Inc (NASDAQ:ENTA) This Quarter

Equities research analysts expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report sales of $48.18 million for the current quarter, Zacks reports. Four analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the highest sales estimate coming in at $52.00 million and the lowest estimate coming in at $44.13 million. Enanta Pharmaceuticals posted sales of $57.26 million in the same quarter last year, which suggests a negative year-over-year growth rate of 15.9%. The business is scheduled to issue its next quarterly earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year sales of $220.45 million for the current financial year, with estimates ranging from $206.93 million to $228.11 million. For the next year, analysts anticipate that the business will post sales of $203.66 million, with estimates ranging from $189.92 million to $214.37 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.29. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The company had revenue of $39.60 million during the quarter, compared to analysts’ expectations of $40.92 million. During the same quarter last year, the company posted $0.61 EPS. The firm’s revenue was down 10.0% compared to the same quarter last year.

Several equities analysts have commented on ENTA shares. BidaskClub cut shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Berenberg Bank raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $80.00 to $120.00 in a research report on Tuesday, April 23rd. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $99.00 price target for the company in a research report on Friday, May 10th. Finally, Wolfe Research started coverage on shares of Enanta Pharmaceuticals in a research report on Friday, May 24th. They issued an “outperform” rating and a $117.00 price target for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $111.20.

Several institutional investors have recently added to or reduced their stakes in the company. Piedmont Investment Advisors Inc. lifted its position in shares of Enanta Pharmaceuticals by 3.4% during the 4th quarter. Piedmont Investment Advisors Inc. now owns 3,762 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 125 shares during the last quarter. TD Asset Management Inc. lifted its position in Enanta Pharmaceuticals by 0.5% in the fourth quarter. TD Asset Management Inc. now owns 31,817 shares of the biotechnology company’s stock valued at $2,254,000 after acquiring an additional 145 shares during the last quarter. Rhumbline Advisers lifted its position in Enanta Pharmaceuticals by 0.3% in the first quarter. Rhumbline Advisers now owns 46,898 shares of the biotechnology company’s stock valued at $4,480,000 after acquiring an additional 145 shares during the last quarter. New York State Teachers Retirement System lifted its position in Enanta Pharmaceuticals by 0.4% in the fourth quarter. New York State Teachers Retirement System now owns 40,065 shares of the biotechnology company’s stock valued at $2,838,000 after acquiring an additional 166 shares during the last quarter. Finally, Mason Street Advisors LLC lifted its position in Enanta Pharmaceuticals by 3.5% in the first quarter. Mason Street Advisors LLC now owns 5,058 shares of the biotechnology company’s stock valued at $483,000 after acquiring an additional 172 shares during the last quarter. 89.64% of the stock is owned by institutional investors and hedge funds.

ENTA stock traded down $11.54 during midday trading on Friday, hitting $85.81. The company’s stock had a trading volume of 721,032 shares, compared to its average volume of 139,479. Enanta Pharmaceuticals has a 52-week low of $64.08 and a 52-week high of $127.77. The stock has a market capitalization of $1.91 billion, a PE ratio of 24.66 and a beta of 1.18.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Recommended Story: What is the Bid-Ask Spread?

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.